MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Puretech Health PLC Company Profile (LON:PRTC)

Consensus Ratings for Puretech Health PLC (LON:PRTC) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 214.25

Analysts' Ratings History for Puretech Health PLC (LON:PRTC)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016Peel HuntReiterated RatingBuyGBX 220View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Liberum CapitalReiterated RatingBuyGBX 196View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Numis Securities LtdReiterated RatingBuyGBX 206View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Jefferies GroupReiterated RatingBuyGBX 235View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Puretech Health PLC (LON:PRTC)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Puretech Health PLC (LON:PRTC)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Puretech Health PLC (LON:PRTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Puretech Health PLC (LON:PRTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/28/2016Scardino,Dame MarjorieInsiderBuy5,000GBX 135£6,750Tweet This Trade  Share This Trade on StockTwits
10/26/2015Ito,JoichiInsiderBuy6,650GBX 149£9,908.50Tweet This Trade  Share This Trade on StockTwits
10/9/2015Scardino,MarjorieInsiderBuy6,890GBX 126£8,681.40Tweet This Trade  Share This Trade on StockTwits
9/28/2015Langer,RobertInsiderBuy7,200GBX 135£9,720Tweet This Trade  Share This Trade on StockTwits
9/16/2015LaMattina,JohnInsiderBuy11,000GBX 146£16,060Tweet This Trade  Share This Trade on StockTwits
9/10/2015LaMattina,JohnInsiderBuy5,492GBX 146£8,018.32Tweet This Trade  Share This Trade on StockTwits
9/9/2015LaMattina,JohnInsiderBuy11,000GBX 147£16,170Tweet This Trade  Share This Trade on StockTwits
9/4/2015LaMattina,JohnInsiderBuy11,000GBX 138£15,180Tweet This Trade  Share This Trade on StockTwits
9/3/2015Scardino,MarjorieInsiderBuy10,000GBX 135£13,500Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Puretech Health PLC (LON:PRTC)
DateHeadline
06/28/16 05:51 PMPuretech Health Plc (LON:PRTC) price target maintained to GBX220 as issued in a report today by Peel Hunt
06/28/16 01:00 AMSonde Health Advances Novel Vocal Biomarker Analysis Platform -
06/26/16 05:01 PMEY Names PureTech Health's Co-Founder and Chief Executive Officer Daphne Zohar as EY Entrepreneur Of The Year® 2016 in New England
06/25/16 05:24 PMEY Names PureTech Health’s Co-Founder and Chief Executive Officer Daphne Zohar as EY Entrepreneur Of The Year ® 2016 in New England
06/24/16 09:04 AMEY Names PureTech Health’s Co-Founder and Chief Executive Officer Daphne Zohar as EY Entrepreneur Of The Year® 2016 in New England -
06/08/16 12:44 PMPureTech Health Plc – Value Analysis (LONDON:PRTC) : June 8, 2016 -
06/07/16 08:42 AMEpiStem Holdings Plc's (EHP) "Buy" Rating Reiterated at Peel Hunt
06/07/16 03:36 AMPureTech Health Plc breached its 50 day moving average in a Bullish Manner : PRTC-GB : June 7, 2016 -
06/06/16 01:00 AMVedanta Biosciences Closes $50 Million Financing to Advance Microbiome Therapeutics -
05/31/16 07:00 AMPureTech to Present at the Jefferies 2016 Healthcare Conference in New York -
05/12/16 12:33 PMReal Estate Investors PLC. (RLE) Rating Reiterated by Liberum Capital - Liberum Capital's price target points to a potential upside of 25.00% from the stock's current price. Puretech Health PLC (LON:PRTC)'s stock had its "buy" rating reissued by equities research analysts at Peel Hunt in a note issued to investors on Wednesday ...
05/12/16 12:33 PMPuretech Health PLC's (PRTC) "Buy" Rating Reiterated at Peel Hunt - Rank Group PLC using EPIC/TICKER code LON:RNK has had its stock rating noted as "Retains" with the recommendation being set at "ADD" this morning by analysts at Peel Hunt. According to this price target, it now means the analyst believes there is a ...
05/10/16 01:00 AMPureTech Launches “Alivio Therapeutics” and Advances Novel Approach for Treating Inflammatory Disease -
05/09/16 12:55 PMPureTech Teams with Siddhartha Mukherjee to Launch Vor … - PureTech Health plc ("PureTech," LSE: PRTC) today announced the launch of Vor BioPharma, an immuno-oncology company dedicated to developing a new class of targeted cell therapies. The company, which is advancing a novel approach to chimeric antigen ...
05/09/16 01:00 AMPureTech Teams with Siddhartha Mukherjee to Launch Vor BioPharma to Advance Novel Targeting Platform to Expand Applicability of CAR T-Cell Immunotherapies in Immuno-Oncology -
05/06/16 01:00 AMAkili Interactive Labs Opens Enrollment for Pivotal Trial of Novel ADHD Treatment -
05/05/16 01:00 AMThe Sync Project Teams with World-Renowned Artists, Peter Gabriel, St. Vincent, Jon Hopkins and Esa-Pekka Salonen, to Advance Music as Medicine -
05/03/16 12:36 PMGelesis200 Positive Safety Results - Gelesis200 PureTech Health plc ("PureTech", LSE: PRTC), a cross-disciplinary healthcare company tackling fundamental healthcare needs, is pleased to note that Gelesis, a PureTech business focused on the development of first-in-class products to safely ...
05/03/16 01:00 AMGelesis Announces Positive Safety Data from First-In-Human Study of Second Product Candidate, Gelesis200 -
05/02/16 10:07 AMPureTech’s Andrew Miller and Ketki Karanam Named to MedTech Boston’s Top 40 Under 40 Healthcare Innovators List -
04/26/16 01:32 PMGelesis : Announces First U.S. Patient Enrolled in Pivotal Gelesis :100 Weight-Loss Study - Gelesis investors include Cormorant Asset Management, PureTech Health PLC (LSE: PRTC), Invesco Asset Management, the Priztker/Vlock Family Office and other prominent biotech and finance investors.
04/26/16 01:32 PMFirst US Patient Enrolled in Gelesis100 Study - Gelesis investors include Cormorant Asset Management, PureTech Health PLC (LSE: PRTC), Invesco Asset Management, the Priztker/Vlock Family Office and other prominent biotech and finance investors. This press release contains statements that are or may be ...
04/26/16 03:00 AMGelesis Announces First U.S. Patient Enrolled in Pivotal Gelesis100 Weight-Loss Study -
04/14/16 07:00 AMVedanta Biosciences Appoints New Senior Vice President of Process Development and Manufacturing and Names New Scientific Advisory Board Member -
04/13/16 10:37 AMPureTech Health Plc :PRTC-GB: Earnings Analysis: 2015 By the Numbers -
04/08/16 12:38 PMPuretech Health PLC's (PRTC) Buy Rating Reaffirmed at Peel Hunt - They now have a GBX 900 ($12.85) price target on the stock.BP plc (LON:BP) opened at 337.3875 on Monday. Seven equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the ...
04/07/16 06:07 AMFull Year 2015 PureTech Health PLC Earnings Release - Time Not Supplied -
04/01/16 12:27 PMDrug companies inject interest into lacklustre London market - PureTech Health (LON:PRTC) told investors it had expanded its focus on microbiome ... looked set to make its AIM debut by reversing into listed investment firm Fastnet Equity PLC (LON:FAST). Amryt Pharmaceuticals will join the London market in a deal ...
03/31/16 11:47 AMExpands Microbiome Focus with "Commense" - executes worldwide license and announces founding scientists and advisors PureTech Health plc ("PureTech", LSE: PRTC), a cross-disciplinary healthcare company tackling fundamental healthcare needs, is pleased to note that Commense, a PureTech business ...
03/31/16 03:00 AMCommense Advances Microbiome Platform Targeting Early Childhood Health -
03/30/16 11:59 AMVedanta Biosciences Announces Licence with RIKEN - PureTech Health plc ("PureTech", LSE: PRTC), a cross-disciplinary healthcare company tackling fundamental medical needs, is pleased to note that Vedanta Biosciences, a PureTech business pioneering the development of a new class of therapies designed to ...
03/30/16 03:41 AMPureTech Health Plc breached its 50 day moving average in a Bearish Manner : PRTC-GB : March 30, 2016 -
03/30/16 03:00 AMVedanta Biosciences Announces License Agreement with RIKEN and other Japanese Institutions for New Immune Boosting Microbiome Technology -
03/16/16 11:52 AMPuretech Health : Vedanta Biosciences : Appoints New Chief Scientific Officer and Expands to New Facility - The Company was founded by PureTech Health (LSE: PRTC) and a group of world-renowned experts in immunology ... risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding ...
03/16/16 11:52 AMVedanta Appoints New Chief Scientific Officer - PureTech Health plc ("PureTech", LSE: PRTC), a new kind of pharmaceutical company taking a cross-disciplinary approach to tackling fundamental healthcare needs, is pleased to note that Vedanta Biosciences, a PureTech business pioneering the development of ...
03/16/16 04:00 AMVedanta Biosciences Appoints New Chief Scientific Officer and Expands to New Facility -
03/14/16 02:56 PMPureTech Health Plc – Value Analysis (LONDON:PRTC) : March 14, 2016 -
03/11/16 03:34 AMPureTech Health Plc breached its 50 day moving average in a Bearish Manner : PRTC-GB : March 11, 2016 -
02/23/16 03:00 AMPureTech to Present at the Cowen and Company 36th Annual Health Care Conference -
02/16/16 10:23 AMPureTech Health PLC (PRTC) - Boston, Massachusetts, February 16, 2016- PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a cross-disciplinary healthcare company developing novel medicines to tackle fundamental healthcare needs in disruptive ways, plans to announce its ...
01/27/16 09:53 AMExpands SAB and appoints new Senior Advisors - 2016 - PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a cross-disciplinary healthcare company developing novel medicines to tackle fundamental healthcare needs in disruptive ways, today announced it has expanded its Scientific Advisory Board ...
01/27/16 03:00 AMPureTech Expands Scientific Advisory Board and Appoints New Senior Advisors -
01/22/16 09:58 AMVideogame Maker Seeks to Treat ADHD - The funding round was led by co-founder PureTech Health PRTC-2.63 % PLC, a Boston-based research-commercialization company. Write to Denise Roland at [email protected]
01/22/16 09:58 AMOperating Company Akili Interactive Labs Raises $30.5 Million to Advance Product Development and Build Commercial Infrastructure - PureTech Health plc ("PureTech", LSE: PRTC), a cross-disciplinary healthcare company developing novel medicines to tackle fundamental healthcare needs in disruptive ways, is pleased to note that its operating company, Akili Interactive Labs, Inc. ("Company ...
01/22/16 09:58 AMOperating Company Akili Raises $30.5 Million - ... Labs Raises $30.5 Million to Advance Product Development and Build Commercial Infrastructure PureTech Health plc ("PureTech", LSE: PRTC), a cross-disciplinary healthcare company developing novel medicines to tackle fundamental healthcare needs in ...
01/22/16 01:00 AMDigital Medicine Company Akili Interactive Labs Raises $30.5 Million to Advance Product Development and Build Commercial Infrastructure -
01/19/16 09:52 AMFirst Capital Markets Meeting - Boston, Massachusetts, January 19, 2016- PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a cross-disciplinary healthcare company developing novel medicines to tackle fundamental healthcare needs in disruptive ways, announces its first ...
01/15/16 11:33 AMPureTech Health Plc – Value Analysis (LONDON:PRTC) : January 15, 2016 -
10/28/15 12:01 PMPilot Study Results Demonstrate Akili’s Mobile Digital Intervention Improved Attention and Working Memory in Pediatric Attention Deficit Hyperactivity Disorder -
10/13/15 07:00 AMVedanta Biosciences Expands Team with Additions of Head of Preclinical Development and Head of Intellectual Property -
About Puretech Health PLC

Puretech Health PLC logoPureTech Health plc is a United Kingdom-based cross-disciplinary healthcare company. The Company's segments are growth stage operating companies, and project phase and sourcing companies. Its Growth stage operating companies segment includes subsidiaries that are engaged in activities, which focus on developing products to solve healthcare problems in various markets. Its Project phase and sourcing companies segment includes subsidiaries that are engaged in activities, which focus on financing, sourcing and creating new operating companies and newly created operating companies, which have technologies in the process of validation. It has a pipeline of over 10 operating companies and a pipeline of over 10 concept phase initiatives resulting from review of approximately 650 ideas annually. The Company focuses on areas, including immune and inflammatory disorders; cognitive and psychiatric disorders; diabetes and obesity; oncology, and infectious diseases.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: PRTC
  • CUSIP:
Key Metrics:
  • Previous Close: $2.11
  • 50 Day Moving Average: $134.25
  • 200 Day Moving Average: $145.70
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $361.88M
  • Current Quarter EPS Consensus Estimate: $-0.27 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha